Published Aug 22, 2026
BioXcel Therapeutics (BTAI): A New Haven-Based Clinical-Stage Neuroscience Company Navigating IGALMI Commercialization and Pipeline Restructuring Under Liquidity Pressure
In-depth research on BTAI covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
2,984 words13 min read
Read report